PEAR 0.00 Stock Price Pear Therapeutics, Inc.
Range: | 0.009-6.74 | Vol Avg: | 10086397 | Last Div: | 0 | Changes: | 0 |
Beta: | 0.52 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Wed Mar 31 2021 | Empoloyees: | 200 |
CUSIP: | 704723105 | CIK: | 0001835567 | ISIN: | US7047231052 | Country: | US |
CEO: | Mr. Christopher D. T. Guiffre J.D., M.B.A., MBA | Website: | https://peartherapeutics.com |
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.